4.10 -0.01 (-0.24%)
After hours: 6:53PM EDT
|Bid||4.07 x 1100|
|Ask||4.10 x 1600|
|Day's range||3.87 - 4.45|
|52-week range||0.67 - 6.96|
|PE ratio (TTM)||3.10|
|Earnings date||13 Mar 2017 - 17 Mar 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||7.00|
If you're on the hunt for small-cap biotechs that could be big winners next year, Amarin, MannKind Corp., and 22nd Century Group need to be on your radar right now.
The company is spending more on interest than it's making in revenue. But can growing sales for Afrezza address fears about MannKind's debt?
Shares of MannKind Corp. tumbled 8.4% in premarket trade Wednesday, after the inhaled therapeutics products maker announced overnight an offering of common stock, as the company takes advantage of a tripling ...
In the past 3 weeks, MannKind has tripled to $6.75, bringing the year-to-date return on Nate Pile's fund to 34.82%. Here's what's behind MannKind's strong gains and what Nate is doing about it.
MannKind (MNKD:Nasdaq) By Maxim Group ($5.30, Oct. 6, 2017) In the wake of recent news that the Food and Drug Administration has approved the label revision for Afrezza (including a demonstration of the “speed” at which Afrezza delivers insulin and manages blood sugar), we see reduced risk in the MannKind story. The result is that our price target on MannKind climbs to $7, from $4.
Mylan The FDA approved the company’s generic version of a multiple-sclerosis treatment that’s been a big seller for Teva and for Momenta. GoPro Alphabet unit Google unveiled a clip-on camera that will be cheaper than some of GoPro’s wearable devices. MBIA After Hurricane Maria blasted Puerto Rico’s bonds, President Trump discouraged hopes for a federal bailout.
MannKind Corp.'s stock rocketed Thursday on very heavy volume, putting it on track to post a third-straight 20+% gain, after the Food and Drug Administration updated prescribing information for the company's ...
MannKind (MNKD:Nasdaq) By Maxim Group ($2.20, Oct. 2, 2017) MannKind announced that the Food and Drug Administration has approved the label revision Afrezza, including for the first time since its 2014 approval demonstration of the “speed” at which Afrezza delivers insulin and manages blood sugar. With the warrants off the table (for 1.3 million common shares), the company will have 22 million available shares and can raise as much as $50 million through its at-the-market (ATM) [stock offerings] as it continues to undergo capital restructuring.